Estrogen responsiveness of IBEP-2, a new human cell line derived from breast carcinoma

Breast Cancer Research and Treatment

Volumn 86, Issue 1, 2004, Pages 39-53

  Journé, Fabrice ^a   Body, Jean Jacques ^a   Leclercq, Guy ^a   Nonclercq, Denis ^b   Laurent, Guy ^b  

^a JULES BORDET INSTITUTE   (Belgium)

^b UNIVERSITY OF MONS   (Belgium)

Author keywords

breast cancer; breast carcinoma; estrogen receptor; MCF 7; MG 132; progesterone receptor; proteasome inhibition; receptor downregulation

Indexed keywords

ANTIESTROGEN; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; DIETHYLSTILBESTROL; ESTROGEN; ESTROGEN RECEPTOR; ESTROGEN RECEPTOR ALPHA; FULVESTRANT; GENISTEIN; PROGESTERONE RECEPTOR; PROTEASOME INHIBITOR; PROTEIN ANTIBODY; TAMOXIFEN;

ARTICLE; BREAST CARCINOMA; CELL GROWTH; CELL LINE; CELL LINE IBEP 2; CELL STIMULATION; CELL STRAIN MCF 7; CONTROLLED STUDY; DOWN REGULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOFLUORESCENCE; MEASUREMENT; MITOGENESIS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION;

BREAST NEOPLASMS; CARCINOMA; CELL DIVISION; DOWN-REGULATION; ESTROGEN RECEPTOR MODULATORS; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOBLOTTING; IMMUNOENZYME TECHNIQUES; LIGANDS; MITOGENS; RECEPTORS, ESTROGEN; TUMOR CELLS, CULTURED;

EID: 3142676483     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:BREA.0000032922.87541.31     Document Type: Article

References (59)

1. Hulka BS, Moorman PG: Breast cancer: hormones and other risk factors. Maturitas 38: 103-116, 2001
2. Key TJ, Verkasalo PK, Banks E: Epidemiology of breast cancer. Lancet Oncol 2: 133-140, 2001
3. Green S, Furr B: Prospects for the treatment of endocrine-responsive tumours. Endocrine-Related Cancer 6: 349-371, 1999
4. Pritchard KI: Current and future directions in medical therapy for breast carcinoma. Cancer 88: 3065-3072, 2000
5. Rønnov-Jessen L, Petersen OW, Bissell MJ: Cellular changes involved in conversion of normal to malignant breast: importance of the stromal reaction. Physiol Rev 76: 69-125, 1996
6. Lacroix M, Leclercq G: Relevance of breast cancer cell lines as models for breast tumours: an update. Breast Cancer Res Treat 83: 249-289, 2004
7. Soule HD, Vazguez J, Long A, Albert S, Brennan M: A human cell line from a pleural effusion from a breast carcinoma. J Natl Cancer Inst 51: 1409-1416, 1973
8. Keydar I, Chen L, Karby S, Weiss FR, Delarea J, Radu M, Chaitcik S, Brenner HJ: Establishment and characterization of a cell line of human carcinoma origin. Eur J Cancer 15: 659-670, 1979
9. Cailleau R, Young R, Olive M, Reeves WJ: Breast tumor cell lines from pleural effusions. J Natl Cancer Inst 53: 661-674, 1974
10. O'Valle F, Aneiros J, Osuna A, Aguilar D, Navarro N, Alvaro T: Human melanoma cell lines: an immunofluorescence and ultrastructural study. J Cutan Pathol 15: 374-379, 1988
11. Siwek B, Larsimont D, Lacroix M, Body J-J: Establishment and characterization of three new breast-cancer cell lines. Int J Cancer 76: 677-683, 1998
12. El Khissiin A, Leclercq G: Implication of proteasome in estrogen receptor degradation. FEBS Lett 448: 160-166, 1999
13. Alarid ET, Bakopoulos N, Solodin N: Proteasome-mediated proteolysis of estrogen receptor: a novel component in autologous down-regulation. Mol Endocrinol 13: 1522-1534, 1999
14. Nawaz Z, Lonard DM, Dennis AP, Smith CL, O'Malley BW: Proteasome-dependent degradation of the human estrogen receptor. Proc Natl Acad Sci USA 96: 1858-1862, 1999
15. Lonard DM, Nawaz Z, Smith CL, O'Malley BW: The 26S proteasome is required for estrogen receptor-α and coactivator turnover and for efficient estrogen receptor-α transactivation. Mol Cell 5: 939-948, 2000
16. Wijayaratne AL, McDonnel DP: The human estrogen receptor-α is a ubiquitinated protein whose stability is affected differentially by agonists, antagonists and selective estrogen receptor modulators. J Biol Chem 276: 35684-35692, 2001
17. Preisler-Mashek MT, Solodin N, Stark BL, Tyriver MK, Alarid ET: Ligand-specific regulation of proteasome-mediated proteolysis of estrogen receptor-α. Am J Physiol Endocrinol Metab 282: E891-E898, 2002
18. Lee M-O, Kim E-O, Kwon HJ, Kim YM, Kang H-J, Kang H, Lee L-E: Radicicol represses the transcriptional function of the estrogen receptor by suppressing the stabilization of the receptor by heat shock protein 90. Mol Cell Endocrinol 188: 47-54, 2002
19. Brohée R, Nonclercq D, Journé F, Toubeau G, Falmagne P, Leclercq G, Heuson-Stiennon J-A, Laurent G: Demonstration of estrogen receptors and of estrogen responsiveness in the HKT-1097 cell line derived from diethylstilbestrol-induced kidney tumors. In Vitro Cell Dev Biol - Animal 36: 640-649, 2000
20. Smith PK, Krohn RI, Hermanson GT, Mallia AK, Gartner FH, Provenzano MD, Fujimoto EK, Goeke NM, Olson BJ, Klenk DC: Measurement of protein using bicinchoninic acid. Anal Biochem 150: 76-85, 1985
21. Bradford MM: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248-254, 1976
22. Stoica A, Saceda M, Fakhro A, Solomon HB, Fenster BD, Martin MB: The role of transforming growth factor-β in the regulation of estrogen receptor expression in the MCF-7 breast cancer cell line. Endocrinology 138: 1498-1505, 1997
23. El Khissiin A, Journé F, Laïos I, Seo H-S, Leclercq G: Evidence of an estrogen receptor form devoid of estrogen binding ability in MCF-7 cells. Steroids 65: 903-913, 2000
24. R-6. Br J Cancer 79: 386-392, 1999
25. Wen DX, Xu YF, Mais DE, Goldman ME, McDonnell DP: The A and B isoforms of the human progesterone receptor operate through distinct signaling pathways within target cells. Mol Cell Biol 14: 8356-8364, 1994
26. Richer JK, Jacobsen BM, Manning NG, Abel MG, Wolf DM, Horwitz KB: Differential gene regulation by the two progesterone receptor isoforms in human breast cancer cells. J Biol Chem 277: 5209-5218, 2002
27. Petterson K, Gustafsson J-Å: Role of estrogen receptor beta in estrogen action. Ann Rev Physiol 63: 165-192, 2001
28. Gustaffson J-Å, Warner M: Estrogen receptor β in the breast: role in estrogen responsiveness and development of breast cancer. J Steroid Biochem Mol Biol 74: 245-248, 2000
29. Vladusic EA, Hornby AE, Guerra-Vladusic FK, Lakins J, Lupu R: Expression and regulation of estrogen receptor β in human breast tumors and cell lines. Oncol Rep 7: 157-167, 2000
30. Jensen EV, Cheng G, Palmieri C, Saji S, Mäkelä S, Van Noorden S, Wahlström T, Warner M, Coombes RC, Gustafsson J-Å: Estrogen receptors and proliferation markers in primary and recurrent breast cancer. Proc Natl Acad Sci USA 98: 15197-15202, 2001
31. Watanabe T, Inoue S, Ogawa S, Ishii Y, Hiroi H, Ikeda K, Orimo A, Muramatsu M: Agonistic effect of tamoxifen is dependent on cell type, ERE-promoter context, and estrogen receptor subtype: functional difference between estrogen receptors α and β. Biochem Biophys Res Commun 236: 140-145, 1997
32. O'Neil JS, Burow ME, Green AE, McLachlan JA, Henson MC: Effects of estrogen on leptin gene promoter activation in MCF-7 breast cancer and JEG-3 choriocarcinoma cells: selective regulation via estrogen receptors α and β. Mol Cell Endocrinol 176: 67-75, 2001
33. Gupta M, McDougal A, Safe S: Estrogenic and antiestrogenic activities of 16α- and 2-hydroxymetabolites of 17β-estradiol in MCF-7 and T47D human breast cancer cells. J Steroid Biochem Mol Biol 67: 413-419, 1998
34. Wijayaratne AL, Nagel SC, Paige LA, Christensen DJ, Norris JD, Fowlkes DM, McDonnel DP: Comparative analyses of mechanistic differences among antiestrogens. Endocrinology 140: 5828-5840, 1999
35. Gutendorf B, Westendorf J: Comparison of an array of in vitro assays for the assessment of the estrogenic potential of natural and synthetic estrogens, phytoestrogens and xenoestrogens. Toxicology 166: 79-89, 2001
36. Camby I, Kiss R: In vitro estradiol-sensitivity characterization of the MCF-7, ZR-45, MDA-MB-231 and T47-D human breast neoplastic cell lines. Anticancer Res 13: 2355-2360, 1993
37. Labrie F, Labrie C, Bélanger A, Simard J, Giguère V, Tremblay A, Tremblay G: EM-652 (SCH57068), a pure SERM having complete antiestrogenic activity in the mammary gland and endometrium. J Steroid Biochem Mol Biol 79: 213-225, 2001
38. Diel P, Smolnikar K, Michna H: The pure antiestrogen ICI 182780 is more effective in the induction of apoptosis and down regulation of BCL-2 than tamoxifen in MCF-7 cells. Breast Cancer Res Treat 58: 87-97, 1999
39. Fazzari A, Catalano MG, Comba A, Becchis M, Raineri M, Frairia R, Fortunati N: The control of progesterone receptor expression in MCF-7 breast cancer cells: effect of estradiol and sex hormone-binding globulin (SHBG). Mol Cell Endocrinol 172: 31-36, 2001
40. Vienonen A, Syvälä H, Miettinen S, Tuohimaa P, Ylikomi T: Expression of progesterone receptor isoforms A and B is differentially regulated by estrogen in different breast cancer cell lines. J Steroid Biochem Mol Biol 80: 307-313, 2002
41. Stoica A, Saceda M, Fakhro A, Joyner M, Martin MB: Role of insulin-like growth factor-I in regulating estrogen receptor-alpha gene expression. J Cell Biochem 76: 605-614, 2000
42. Conneely OM, Mulac-Jericevic B, Lydon JP, De Mayo FJ: Reproductive functions of the progesterone receptor isoforms: lessons from knock-out mice. Mol Cell Endocrinol 179: 97-103, 2001
43. Graham JD, Yeates C, Balleine RL, Harvey SS, Milliken JS, Bilous AM, Clarke CL: Characterization of progesterone receptor A and B expression in human breast cancer. Cancer Res 55: 5063-5068, 1995
44. Bamberger AM, Milde-Langosch K, Schulte HM, Loning T: Progesterone receptor isoforms, PR-B and PR-A, in breast cancer: correlations with clinicopathologic tumor parameters and expression of AP-1 factors. Horm Res 54: 32-37, 2000
45. Jacobsen BM, Richer JK, Schittone SA, Horwitz KB: New human breast cancer cells to study progesterone receptor isoform ratio effects and ligand-independent gene regulation. J Biol Chem 277: 27793-27800, 2002
46. Sartorius CA, Shen T, Horwitz KB: Progesterone receptors A and B differentially affect the growth of estrogen-dependent human breast tumor xenografts. Breast Cancer Res Treat 79: 287-299, 2003
47. Pink JJ, Jordan VC: Models of estrogen receptor regulation by estrogens and antiestrogens in breast cancer cell lines. Cancer Res 56: 2321-2330, 1996
48. Legros N, Jin L, Leclercq G: Tamoxifen-induced estrogen receptor up-regulation in mammary tumor cells is not related to growth inhibition. Cancer Chemother Pharmacol 39: 380-382, 1997
49. Seo HS, Larsimont D, Querton G, El Khissiin A, Laios I, Legros N, Leclercq G: Estrogenic and anti-estrogenic regulation of estrogen receptor in MCF-7 breast-cancer cells: comparison of immunocytochemical data with biochemical measurements. Int J Cancer 78: 760-765, 1998
50. Laïos I, Journe F, Laurent G, Nonclercq D, Toillon R-A, Seo H-S, Leclercq G: Mechanisms governing the accumulation of estrogen receptor alpha in MCF-7 breast cancer cells treated with hydroxytamoxifen and related antiestrogens. J Steroid Biochem Mol Biol 87: 207-221, 2003
51. Davis MD, VanderKuur JA, Brooks SC: Ligand structure influences autologous downregulation of estrogen receptor-alpha messenger RNA. J Steroid Biochem Mol Biol 70: 27-37, 1999
52. Qualmann B, Kessels MM, Thole HH, Sierralta WD: A hormone pulse induces transient changes in the subcellular distribution and leads to a lysosomal accumulation of the estradiol receptor α in target tissues. Eur J Cell Biol 79: 383-393, 2000
53. Lange CA, Shen T, Horwitz KB: Phosphorylation of human progesterone receptors at serine-294 by mitogen-activated protein kinase signals their degradation by the 26S proteasome. Proc Natl Acad Sci USA 97: 1032-1037, 2000
54. Dace A, Zhao L, Park KS, Furuno T, Takamura N, Nakanishi M, West BL, Hanover JA, Cheng S: Hormone binding induces rapid proteasome-mediated degradation of thyroid hormone receptors. Proc Natl Acad Sci USA 97: 8985-8990, 2000
55. Osburn DL, Shao G, Seidel HM, Schulman IG: Ligand-dependent degradation of retinoid X receptors does not require transcription activity or coactivator interactions. Mol Cell Biol 21: 4909-4918, 2001
56. Deroo BJ, Rentsch C, Sampath S, Young J, DeFranco DB, Archer TK: Proteasomal inhibition enhances glucocorticoid receptor transactivation and alters its subnuclear trafficking. Mol Cell Biol 22: 4113-4123, 2002
57. Wormke M, Stoner M, Saville B, Safe S: Crosstalk between estrogen α and the aryl hydrocarbon receptor in breast cancer cells involves unidirectional activation of proteasomes. FEBS Lett 478: 109-112, 2000
58. Alarid ET, Preisler-Mashek MT, Solodin NM: Thyroid hormone is an inhibitor of estrogen-induced degradation of estrogen receptor-alpha protein: estrogen-dependent proteolysis is not essential for receptor transactivation function in the pituitary. Endocrinology 144: 3469-3476, 2003
59. Nardulli AM, Greene GL, O'Malley BW, Katzenellenbogen BS: Regulation of progesterone receptor messenger ribonucleic acid and protein levels in MCF-7 cells by estradiol: analysis of estrogen's effect on progesterone receptor synthesis and degradation. Endocrinology 122: 935-944, 1988